GENinCode PLC, traded on the NYSE under the symbol GENI, is a company focused on developing and commercializing innovative genetic testing products. The company recently caught attention when New Street set a price target of $17 for its stock, which was trading at $11.32 at the time. This suggests a potential price increase of about 50.18%.
The stock's recent performance has been notable. GENI's price has increased by approximately 11.97%, or $1.21, reaching $11.32. The stock has fluctuated between $10.64 and $11.58 during the day. Over the past year, it has seen a high of $13.73 and a low of $8.15, indicating some volatility.
A significant factor contributing to GENI's recent surge is its partnership with Thermo Fisher Scientific. This collaboration involves Thermo Fisher manufacturing, selling, and distributing GENinCode's CARDIO inCode-Score test. The test will initially be available in the US as a Lab Developed Test, pending FDA clearance.
This partnership is crucial for GENinCode, as it leverages Thermo Fisher's QuantStudio 5 Dx real-time PCR system, ensuring broad market reach. The companies plan to scale up manufacturing to meet growing demand, which could positively impact GENI's stock performance and market capitalization, currently at $2.7 billion.
